Literature DB >> 12971668

A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting.

C R MacIntyre1, K Goebel, G V Brown, S Skull, M Starr, R O Fullinfaw.   

Abstract

SETTING: A randomised, controlled clinical trial of the effectiveness of a family-based programme of directly observed treatment (DOT) for tuberculosis.
METHODS: TB patients seen in Victoria, Australia, were randomly allocated to DOT observed by a family member (FDOT), or to standard supervised but non-observed therapy (ST). The outcome measure was compliance, measured by blinded testing of isoniazid levels in urine. An intention-to-treat analysis was used.
RESULTS: Of 173 patients, 87 were allocated to FDOT and 86 to ST. Only 58% in the FDOT group were able to receive FDOT, the major reason being living alone and not having a family member to observe treatment. The rate of non-compliance was 24% (41/173), with no significant difference between FDOT (22/87) and ST (19/86). No clinical or socio-demographic variable predicted compliance.
CONCLUSIONS: We were unable to demonstrate a benefit of FDOT in an urban, industrialised country setting. FDOT may be more appropriate in developing countries, where extended family support is often available and the burden of TB is much higher. Poor compliance and the difficulty in predicting non-compliance shown in this study highlights the need for DOT for all TB patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971668

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  16 in total

1.  DOT associated with reduced all-cause mortality among tuberculosis patients in Taipei, Taiwan, 2006-2008.

Authors:  Y-F Yen; T C Rodwell; M-Y Yen; H-C Shih; B-S Hu; L-H Li; Y-H Shie; P Chuang; R S Garfein
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

Review 2.  Interventions for enhancing medication adherence.

Authors:  Robby Nieuwlaat; Nancy Wilczynski; Tamara Navarro; Nicholas Hobson; Rebecca Jeffery; Arun Keepanasseril; Thomas Agoritsas; Niraj Mistry; Alfonso Iorio; Susan Jack; Bhairavi Sivaramalingam; Emma Iserman; Reem A Mustafa; Dawn Jedraszewski; Chris Cotoi; R Brian Haynes
Journal:  Cochrane Database Syst Rev       Date:  2014-11-20

Review 3.  Tuberculosis (HIV-negative people).

Authors:  Lilia E Ziganshina; Michael Eisenhut
Journal:  BMJ Clin Evid       Date:  2011-03-11

Review 4.  Tuberculosis (HIV-negative people).

Authors:  Lilia E Ziganshina; Paul Garner
Journal:  BMJ Clin Evid       Date:  2009-04-14

5.  Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study.

Authors:  Saidi Egwaga; Abdallah Mkopi; Nyagosya Range; Vera Haag-Arbenz; Amuri Baraka; Penny Grewal; Frank Cobelens; Hassan Mshinda; Fred Lwilla; Frank van Leth
Journal:  BMC Med       Date:  2009-12-21       Impact factor: 8.775

Review 6.  Tuberculosis (HIV-negative people): improving adherence.

Authors:  Liliya Eugenevna Ziganshina; Michael Eisenhut
Journal:  BMJ Clin Evid       Date:  2015-08-11

Review 7.  Antiplatelet combinations for prevention of atherothrombotic events.

Authors:  Mario Bollati; Fiorenzo Gaita; Matteo Anselmino
Journal:  Vasc Health Risk Manag       Date:  2011-01-12

Review 8.  Directly observed therapy for treating tuberculosis.

Authors:  Jamlick Karumbi; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-29

9.  Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation.

Authors:  Victoria A Wade; Jonathan Karnon; Jaklin A Eliott; Janet E Hiller
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Directly observed therapy reduces tuberculosis-specific mortality: a population-based follow-up study in Taipei, Taiwan.

Authors:  Yung-Feng Yen; Muh-Yong Yen; Yi-Ping Lin; Hsiu-Chen Shih; Lan-Huei Li; Pesus Chou; Chung-Yeh Deng
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.